Accordingly, in three patients with cholangiocarcinoma treated with BGJ398 (phase II study, NCT02160041) the FGFR2-BICC1 fusion decreased in cfDNA upon initiation of treatment and increased at the time of radiological progression (81). This evidence concerns the gene FGFR2 and cholangiocarcinoma.